`___________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`
`
`
`COALITION FOR AFFORDABLE DRUGS V LLC;
`HAYMAN CREDES MASTER FUND, L.P.;
`HAYMAN ORANGE FUND SPC – PORTFOLIO A;
`HAYMAN CAPITAL MASTER FUND, L.P.;
`HAYMAN CAPITAL MANAGEMENT, L.P.;
`HAYMAN OFFSHORE MANAGEMENT, INC.;
`HAYMAN INVESTMENTS, LLC;
`NXN PARTNERS, LLC;
`IP NAVIGATION GROUP, LLC;
`J KYLE BASS; and ERICH SPANGENBERG,
`Petitioner,
`
`v.
`
`BIOGEN MA INC.,
`Patent Owner.
`
`____________________________________________
`
`Case: IPR2015-01993
`U.S. Patent No. 8,399,514
`____________________________________________
`
`BIOGEN’S REQUEST FOR ORAL ARGUMENT UNDER 37 C.F.R. § 42.70
`
`
`
`
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`Patent Owner Biogen MA Inc. respectfully requests oral argument in
`
`IPR2015-01993 under 37 C.F.R. § 42.70(a) and pursuant to the Joint Stipulation
`
`(Paper 44) moving Due Date 4 from October 26, 2016, to November 2, 2016.
`
`Pursuant to the Scheduling Orders of March 22, 2016 (Paper 21), and April 16,
`
`2016 (Paper 34), as well as the Order of October 25, 2016 (Paper 56), oral
`
`argument is currently scheduled for November 30, 2016. Oral argument will focus
`
`on the instituted grounds of unpatentability for claims 1-20 of U.S. Patent No.
`
`8,399,514 (Paper 20). The principal issues to be argued will include:
`
`
`
`
`
`
`
`
`
`
`
`Biogen’s entitlement to the February 8, 2007 filing date of U.S.
`
`Provisional Application No. 60/888,921 (Ex. 1012).
`
`The disqualification of Joshi ’999 (Ex. 1030) as prior art under 35
`
`U.S.C. § 103(c)(1).
`
`The patentability of claims 1-20 over the prior art relied upon in
`
`Grounds 1-3 of the Institution Decision under 35 U.S.C. § 103(a).
`
`Biogen’s objective evidence of nonobviousness.
`
`The improper new arguments and evidence concerning alleged
`
`obviousness contained in Petitioner’s Reply to Biogen’s Opposition
`
`(Paper 46) and Dr. Pleasure’s declaration (Ex. 1045) that are outside
`
`the scope of a proper reply in violation of 37 C.F.R. § 42.23(b).
`
`1
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`(Time permitting) The unavailability of Kappos 2006 (Ex. 1003A) as
`
`
`
`prior art based on Dr. O’Neill’s conception of the invention by
`
`February 19, 2004, and Biogen’s diligence from before May 30, 2006,
`
`until February 8, 2007.
`
`
`
`Any additional issues raised by Petitioner in a request for oral
`
`argument, a motion to exclude (if any), or any other motion or paper
`
`filed by Petitioner before oral argument.
`
`Biogen requests the ability to use audio-visual equipment to display
`
`demonstrative exhibits, including a projector and screen to display PowerPoint
`
`slides. If this request for oral hearing is granted, Biogen will direct its requests for
`
`audio-visual equipment to Trials@uspto.gov.
`
`Biogen requests to reserve a portion of its allotted twenty minutes to respond
`
`to any arguments presented by Petitioner.
`
`Dated: November 2, 2016
`
`
`
`
`
`Respectfully submitted,
`
`By: /Michael J. Flibbert /
`
`
`Michael J. Flibbert, Reg. No. 33,234
`Maureen D. Queler, Reg. No. 61,879
`Erin M. Sommers, Reg. No. 60,974
`Finnegan, Henderson, Farabow, Garrett
` & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4000
`Counsel for Patent Owner in
`IPR2015-01993
`
`2
`
`
`
`Case No. IPR2015-01993
`Patent 8,399,514
`
`CERTIFICATE OF SERVICE
`The undersigned certifies that a copy of the foregoing BIOGEN’S
`
`REQUEST FOR ORAL ARGUMENT UNDER 37 C.F.R. § 42.70 was served
`
`electronically via e-mail on November 2, 2016, in its entirety on the following:
`
`James T. Carmichael
`Carol A. Spiegel
`Carmichael IP, PLLC
`8000 Towers Crescent Drive, 13th Floor
`Tysons Corner, VA 22182
`jim@carmichaelip.com
`carol@carmichaelip.com
`
`Petitioner has agreed to electronic service.
`
`By: / Maureen D. Queler /
`Maureen D. Queler
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP
`
`
`
`
`
`
`
`
`
`
`
`Dated: November 2, 2016